Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases

Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2126-31. doi: 10.1073/pnas.0506877103. Epub 2006 Feb 1.

Abstract

Despite three decades of extensive studies on human apolipoprotein A-I (apoA-I), the major protein component in high-density lipoproteins, the molecular basis for its antiatherogenic function is elusive, in part because of lack of a structure of the full-length protein. We describe here the crystal structure of lipid-free apoA-I at 2.4 A. The structure shows that apoA-I is comprised of an N-terminal four-helix bundle and two C-terminal helices. The N-terminal domain plays a prominent role in maintaining its lipid-free conformation, indicating that mutants with truncations in this region form inadequate models for explaining functional properties of apoA-I. A model for transformation of the lipid-free conformation to the high-density lipoprotein-bound form follows from an analysis of solvent-accessible hydrophobic patches on the surface of the structure and their proximity to the hydrophobic core of the four-helix bundle. The crystal structure of human apoA-I displays a hitherto-unobserved array of positively and negatively charged areas on the surface. Positioning of the charged surface patches relative to hydrophobic regions near the C terminus of the protein offers insights into its interaction with cell-surface components of the reverse cholesterol transport pathway and antiatherogenic properties of this protein. This structure provides a much-needed structural template for exploration of molecular mechanisms by which human apoA-I ameliorates atherosclerosis and inflammatory diseases.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Retracted Publication

MeSH terms

  • Apolipoprotein A-I / chemistry*
  • Apolipoprotein A-I / therapeutic use
  • Cardiotonic Agents / chemistry*
  • Cardiotonic Agents / therapeutic use
  • Cardiovascular Diseases / drug therapy
  • Crystallography
  • Humans
  • Hydrophobic and Hydrophilic Interactions
  • Lipids / chemistry
  • Protein Structure, Secondary

Substances

  • Apolipoprotein A-I
  • Cardiotonic Agents
  • Lipids

Associated data

  • PDB/2A01